Share

GICC 2016 will highlight primary therapy of early GI cancer with a focus on pancreatic and biliary cancer

The 3rd St. Gallen International Gastrointestinal Cancer Conference, #GICC2016, will address primary therapy of early GI cancer with a strong focus on pancreatic and biliary cancer. This conference will be held in St. Gallen, Switzerland from 10-12 March 2016.

The interactive program offers sessions on cystic neoplasms of the pancreas, extrahepatic cholangiocarcinoma, cancer of the ampulla of vater, understanding pancreatic cancer, resectable pancreatic cancer, borderline resectable pancreatic cancer, and improving outcome in pancreatic cancer.

Keynote lectures will be given by Dr Manuel Hidalgo of the Spanish National Cancer Research Centre on Molecular biology of pancreatic cancer and by Dr Andrew Rhim of the University of Michigan Medical School on Complex roles of the stroma in pancreatic cancer.

A special session concerning optimal primary therapy of pancreatic cancer will seek consensus on evidence and opinions about the optimal treatment of pancreatic cancer. This session will allow conference participants to share their thoughts on this area of GI cancer as well as benefit from the views and opinions of experts in the field.

There will also be poster exhibitions, an exhibition hall, and industry sponsored satellite symposiums.

Abstract submission is open until 15 December 2015.

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023